You are here

CAR-T

Celgene strikes Obsidian deal to boost CAR-T options

Celgene strikes Obsidian deal to boost CAR-T options

Fierce Biotech

Obsidian Therapeutics

Flag link:

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Yahoo/Reuters

Flag link:

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Fierce Pharma

Flag link:

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

Endpoints

Poseida Therapeutics

Flag link:

Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Xconomy

Poseida Therapeutics

Flag link:

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

Xconomy

Gilead Sciences

Flag link:

TCR2 Shoots for $100 Million IPO in Early 2019

TCR2 Shoots for $100 Million IPO in Early 2019

BioSpace

TCR2 Therapeutics

Flag link:

Novartis seeks to acquire French CAR-T contract manufacturer

Novartis seeks to acquire French CAR-T contract manufacturer

Biopharma Dive

Flag link:

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

Endpoints

Flag link:

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Fierce Pharma

drug manufacturing

Flag link:

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

BioSpace

Flag link:

Weekend ASH presentations hint at future of BCMA CARs

Weekend ASH presentations hint at future of BCMA CARs

BioCentury

Multiple Myeloma

Flag link:

ASH18: Legend's CAR-T brought back to reality

ASH18: Legend's CAR-T brought back to reality

Biopharma Dive

Multiple Myeloma

Flag link:

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

Endpoints

Flag link:

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Fierce Pharma

Flag link:

ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test

ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test

Biopharma Dive

Flag link:

ASH18: CAR-T shows up in early CLL test

ASH18: CAR-T shows up in early CLL test

Biopharma Dive

Flag link:

Novartis focusing on cutting CAR-T costs ahead of EU launches

Novartis focusing on cutting CAR-T costs ahead of EU launches

Pharmaforum

Flag link:

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

BioCentury

Spotlight Therapeutics

Flag link:

Novartis’ CAR-T cancer drug available on NHS to young people

Novartis’ CAR-T cancer drug available on NHS to young people

Pharmaforum

refractory B-cell acute lymphoblastic leukemia

Flag link:

Pages